Gryphon Financial Partners LLC lifted its stake in Icon Plc (NASDAQ:ICLR) by 209.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,685 shares of the medical research company’s stock after buying an additional 1,141 shares during the period. Gryphon Financial Partners LLC’s holdings in Icon were worth $259,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ICLR. Private Advisor Group LLC grew its stake in shares of Icon by 186.6% in the second quarter. Private Advisor Group LLC now owns 8,404 shares of the medical research company’s stock worth $1,111,000 after purchasing an additional 5,472 shares during the last quarter. Atria Investments LLC grew its stake in shares of Icon by 18.5% in the third quarter. Atria Investments LLC now owns 6,556 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 1,024 shares during the last quarter. Dorsey Wright & Associates bought a new stake in shares of Icon in the third quarter worth about $6,644,000. Envestnet Asset Management Inc. grew its stake in shares of Icon by 376.6% in the second quarter. Envestnet Asset Management Inc. now owns 88,669 shares of the medical research company’s stock worth $11,751,000 after purchasing an additional 70,064 shares during the last quarter. Finally, First Republic Investment Management Inc. grew its stake in shares of Icon by 11.9% in the second quarter. First Republic Investment Management Inc. now owns 10,947 shares of the medical research company’s stock worth $1,451,000 after purchasing an additional 1,163 shares during the last quarter. Hedge funds and other institutional investors own 87.62% of the company’s stock.

Icon stock opened at $138.46 on Friday. The company has a current ratio of 2.17, a quick ratio of 2.17 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.77 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 2.06 and a beta of 0.50. Icon Plc has a fifty-two week low of $101.22 and a fifty-two week high of $155.33.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, October 24th. The medical research company reported $1.54 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.54. The business had revenue of $655.02 million for the quarter, compared to analysts’ expectations of $654.66 million. Icon had a return on equity of 26.08% and a net margin of 12.88%. As a group, analysts forecast that Icon Plc will post 6.08 earnings per share for the current year.

ICLR has been the topic of several recent analyst reports. SunTrust Banks raised their target price on Icon to $153.00 and gave the stock a “buy” rating in a research note on Thursday, July 26th. Robert W. Baird reissued a “buy” rating and issued a $154.00 target price on shares of Icon in a research note on Thursday, July 26th. Zacks Investment Research cut Icon from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. Mizuho set a $146.00 target price on Icon and gave the stock a “hold” rating in a research note on Monday, August 6th. Finally, BidaskClub cut Icon from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 21st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $148.00.

ILLEGAL ACTIVITY WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/11/10/gryphon-financial-partners-llc-has-259000-stake-in-icon-plc-iclr.html.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Recommended Story: Growth Stocks

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.